WALTHAM, Mass. - Following a collaborative process with the U.S. Food and Drug Administration (FDA), Alere Inc. (NYSE:ALR) will be initiating a voluntary withdrawal of the Alere INRatio and INRatio2 ...
Alere has announced that its point-of-care INRatio and INRatio2 PT/INR Monitoring System, which was used to measure coagulation levels in the ROCKET AF trial, will be withdrawn from the market ...
Alere Inc will be initiating a voluntary withdrawal of the Alere INRatio and INRatio2 prothrombin time/international normalized ratio (PT/INR) monitoring system because of the potential for the ...
Alere has announced a voluntary withdrawal of the Alere INRatio and INRatio 2 PT/INR Monitoring System. Alere has announced a voluntary withdrawal of the Alere INRatio and INRatio 2 PT/INR Monitoring ...
Evidence-based recommendations on the CoaguChek XS system for self-monitoring coagulation status in adults and children. The recommendations originally included the InRatio2 PT/INR, but this was ...
MINNEAPOLIS, July 11, 2023 /PRNewswire/ -- ARKRAY USA, Inc., a leader in diabetes and resident care solutions to long-term care facilities, announced today the launch of Assure PT Care PT/INR ...
Continuing to address concerns about the device used to measure international normalized ratio (INR) values in ROCKET AF, trial leaders have released additional analyses of stored blood samples ...
FREMONT, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- CoaguSense, Inc., a subsidiary of i-SENS (KOSDAQ:099190), today announced that it has received approval for the sale of the Coag-Sense ® PT/INR ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback